DMP-543 (XR-543) is a potassium channel (KV7 channel) blocker that enhances neurotransmitter release.

Physicochemical Properties

Molecular Formula	C26H18F2N2O
Molecular Weight	412.4398
Exact Mass	412.139
Elemental Analysis	C, 75.72; H, 4.40; F, 9.21; N, 6.79; O, 3.88
CAS #	160588-45-4
PubChem CID	9887884
Appearance	White to yellow solid powder
Density	1.319g/cm3
Boiling Point	593.1ºC at 760mmHg
Flash Point	312.5ºC
Vapour Pressure	0mmHg at 25°C
Index of Refraction	1.643
LogP	5.07
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	4
Heavy Atom Count	31
Complexity	591
Defined Atom Stereocenter Count	0
SMILES	FC1C=C(CC2(CC3C=CN=C(F)C=3)C3C(=CC=CC=3)C(=O)C3=C2C=CC=C3)C=CN=1
InChi Key	MUJBUUDUXGDXLW-UHFFFAOYSA-N
InChi Code	InChI=1S/C26H18F2N2O/c27-23-13-17(9-11-29-23)15-26(16-18-10-12-30-24(28)14-18)21-7-3-1-5-19(21)25(31)20-6-2-4-8-22(20)26/h1-14H,15-16H2
Chemical Name	10,10-bis[(2-fluoropyridin-4-yl)methyl]anthracen-9-one
Synonyms	DMP543; XR-543; DMP-543
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	DMP-543, with an EC50 of 700 nM, increases the release of [3H]ACh in rat brain slices [2].
References	[1]. KV7 channels regulate muscle tone and nonadrenergic noncholinergic relaxation of the rat gastric fundus. Pharmacol Res. 2011 Oct;64(4):397-409. [2]. Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine. J Pharmacol Exp Ther. 1998 May;285(2):724-30.
Additional Infomation	10,10-bis[(2-fluoro-4-pyridinyl)methyl]-9-anthracenone is a member of anthracenes.

Solubility Data

Solubility (In Vitro)

DMSO : ~100 mg/mL (~242.47 mM)

Solubility (In Vivo)

Solubility in Formulation 1: 2.5 mg/mL (6.06 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (6.06 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.4246 mL	12.1230 mL	24.2460 mL
	5 mM	0.4849 mL	2.4246 mL	4.8492 mL
	10 mM	0.2425 mL	1.2123 mL	2.4246 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.